New spinal injection drug enters first human tests for Alzheimer's
NCT ID NCT07214727
Summary
This is a first-in-human study to check if a new drug called ALN-5288 is safe for people with Alzheimer's disease. The drug is injected into the spinal fluid. Researchers will enroll 50 adults with mild to moderate Alzheimer's to monitor for side effects and see how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGMontreal, H3G 1H9, Canada
-
Clinical Trial Site
RECRUITINGOttawa, K1Z 1G3, Canada
-
Clinical Trial Site
RECRUITINGToronto, M3B 2S7, Canada
-
Clinical Trial Site
NOT_YET_RECRUITINGToronto, M5T 2S8, Canada
-
Clinical Trial Site
NOT_YET_RECRUITINGGlasgow, G51 4TF, United Kingdom
-
Clinical Trial Site
RECRUITINGLondon, WC1N 3BG, United Kingdom
Conditions
Explore the condition pages connected to this study.